Introduction
============

Hospital medicine has advanced greatly in the past few decades. Patients with complex medical and surgical disorders are surviving longer due to equally complex medical and surgical interventions, which often involve "collateral damage" by avoiding normal body defensive mechanisms.

Invasive fungal infections (IFIs) in adult patients, especially in the critical care setting, solid organ transplant (SOT), and hematological patients, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to their increasing incidence, high morbidity and mortality rates, and associated health care costs. Early diagnosis and treatment are associated with a better prognosis. Although at present, the number of systemic antifungal agents has increased significantly, the choice of antifungal drug must be based on the individual characteristics of the patient, clinical scenario, and the presence of hemodynamic instability. A tailored therapy (de-escalation) must also be considered in some clinical situations.

Different possible strategies based on diagnoses stage has been described as prophylactic, empiric, pre-emptive and targeted antifungal therapy ([Figure 1](#f1-tcrm-4-1261){ref-type="fig"}). Prophylactic treatment refers to the preventive administration of an antifungal agent to patients at risk of IFI without attributable signs and symptoms. Empiric treatment is defined as the initiation of antifungal treatment in patients at high risk of IFIs and established clinical signs and symptoms, but without microbiological documentation, whereas preemptive therapy is applied when the decision of treatment is based on early diagnostic test. Finally, targeted therapy needs a pathogen identification to be defined.

The aim of this multidisciplinary review was to analyze the best option for treating this special population of adults patients, describing the antifungal armamentarium, making an approach to the mycology laboratory diagnosis and finally developing a state of the art clinical scenario (critically ill, hematological and transplant patients) trying to choose the best strategy for each clinical situation (prophylaxis, empirical, pre-emptive, or targeted therapy).

Role of the mycology laboratory in the antifungal therapy options
=================================================================

Microbiological diagnosis for preventive treatment
--------------------------------------------------

The incidence of IFIs has steadily increased in the past two decades. These infections represent an additional difficulty in the management of immunocompromised patients and are a contributory cause of death in allogeneic hematopoietic stem cell and SOT recipients and in patients undergoing intensive chemotherapy ([@b22-tcrm-4-1261]).

The high mortality associated with IFIs is partly correlated to the difficulties of making an early diagnosis due to the nonspecific clinical features and the low sensitivity of microscopy, histological examination, conventional radiology and cultures of specimens obtained from at-risk patients ([@b53-tcrm-4-1261]). However, improved survival can be obtained by earlier initiation of antifungal therapy. The time period between the biological onset of a fungal infection and the appearance of clinical signs and symptoms represents a window of opportunity that, if identified through prospective screening, may allow for pre-emptive therapeutic intervention. In this diagnostic area, progress could come from prospective screening strategies using new serodiagnostic assays (galactomannan and (1--3)-β-[d]{.smallcaps}-glucan) and/or polymerase chain reaction (PCR) techniques for the detection of fungal-specific DNA.

Thus, to improve earlier diagnosis and survival of IFIs, new nonculture-based microbiological tools should be used in conjunction with modern imaging techniques in addition to conventional microbiological, histological, and radiological procedures.

Nonculture-based microbiological tools
--------------------------------------

With the aim of improving the rapid and early diagnosis of IFIs, new microbiological nonculture-based assays have been developed in the last years, including detection of fungal galactomannan, (1--3)-β-[d]{.smallcaps}-glucan antigen, *Candida albicans* germ tube antibodies and fungal DNA.

### Galactomannan detection

Galactomannan (GM) is a polysaccharide cell wall component released by the *Aspergillus* species during hyphal growth. The detection of galactomannan by sandwich-enzyme immunoassay (EIA), Platelia Aspergillus (Bio-Rad Laboratories, Marnes-La-Coquette, France), has been approved in Europe and the USA for use in hematopoietic stem cell transplant (HSCT) recipients. Furthermore, its detection in body fluids (mainly serum and bronchoalveolar lavage) was included in the 2002 EORTC-MSG consensus definitions of invasive aspergillosis (IA) as a microbiological criterion having the same weight as the isolation of *Aspergillus* spp. or the microscopic demonstration of hyphae from a nonsterile body site ([@b8-tcrm-4-1261]).

Using EIA, circulating galactomannan may be detected at a median of 5--8 days (range 1--27 days) before clinical signs and symptoms of IA become evident. Furthermore, the concentration of circulating galactomannan corresponds with the fungal tissue burden and may therefore be used to monitor the patient's response to antifungal treatment ([@b75-tcrm-4-1261]).

The results of the unique meta-analysis published of the diagnostic value of GM detection with the Platelia Aspergillus^®^ assay have shown that for proven and probable cases of IA, the pooled (adults and pediatrics) sensitivity was only 61% whereas the overall specificity was 93%. In general, the negative predictive value and the specificity are excellent (\>95%), suggesting that the assay can be used to rule out the diagnosis of IA ([@b108-tcrm-4-1261]). False-positive results have been reported in adults (5.7%--14%), but among pediatric patients and neonates these are notably higher (83%) ([@b142-tcrm-4-1261]). Reasons for false reactivity remain largely unknown, although piperacillin -- tazobactam could be a cause of cross-reactivity in adults ([@b142-tcrm-4-1261]), and cross-reacting epitopes from *Bifidobacterium* spp. were proposed as a cause in neonates ([@b82-tcrm-4-1261]). In summary, the GM assay has moderate accuracy for the diagnosis of IA in immunocompromised patients. The test is more useful in patients who have hematological malignancies or who have undergone hematopoietic cell transplantation than in solid-organ transplant recipients. Nevertheless, some important issues in relation to the performance of this assay still remain unanswered, such as the impact of antifungal prophylaxis, the influence of therapy with fungal cell wall inhibitors, or the handling of false-positive and false-negative values ([@b73-tcrm-4-1261]).

Recenty, a very interesting study has evaluated GM detection in BAL fluid in critically ill patients with signs of pneumonia. Patients were classified as having proven, probable, or possible IA. Using a cutoff index of 0.5, the sensitivity and specificity of GM detection in BAL fluid was 88% and 87%, respectively. The sensitivity of serum GM was only 42%. In 11 of 26 proven cases of IA, BAL culture and serum GM remained negative, whereas GM in BAL was positive. Following these rresults GM detection in BAL fluid could be useful in establishing or excluding the diagnosis of IA in intensive care units (ICU) ([@b81-tcrm-4-1261]).

### Detection of (1,3)-β-[d]{.smallcaps}-glucan

Glucans are a cell wall component of most pathogenic fungi except Zygomycetes and *Cryptococcus* spp. (1--3)-β-[d]{.smallcaps}-glucan can be detected in serum in amounts as low as 1 pg/ml by commercial assays. One of them, Fungitell (Associates of Cape Cod Inc., East Falmout, MA), has been approved by the FDA as an adjunct for the diagnosis of IFIs in the USA, based on its evaluation in hematological patients ([@b94-tcrm-4-1261]). At a cut-off of 60 pg/ml, the negative predictive value of twice-weekly sampling was 100%, and sensitivity was 100% if one positive assay was considered a positive result. Furthermore, the results were not influenced by the use of prophylactic or empirical antifungals. (1,3)-β-[d]{.smallcaps}-glucan is a broad spectrum fungal marker and can detect invasive infections due to *Aspergillus*, *Candida*, *Fusarium*, *Acremonium*, *Scedosporium*, *Pneumocystis jiroveci*, etc., but, after a positive result, the invasive infection must be assessed using radiological and microbiological techniques. To date, overall experience with this test remains limited; furthermore, its methodological concerns (use of endotoxin-free and glucan-free glassware) and false-positive results (due to albumin, immunoglobulins, glucan-containing gauze, hemodialysis or Gram-positive bacteremia) make its use difficult in a clinical setting. However, based on the excellent negative predictive value, detection of (1--3)-β-[d]{.smallcaps}-glucan seems to be most useful for excluding IFIs ([@b111-tcrm-4-1261]).

Multicenter clinical trial results have demonstrated that (1,3)-β-[d]{.smallcaps}-glucan assay can be used in clinical specimens with a high specificity and positive predictive value for subjects with proven or probable IFI when compared with control subjects ([@b95-tcrm-4-1261]). This test appears to be useful both as a single-point assay for hospitalized patients with a possible fungal infection and as part of a surveillance strategy in high-risk patients. A cut-off value of 60 or 80 pg/mL appears to be optimal for this test. At a cutoff of 60 pg/mL, the sensitivity and specificity of the assay were 69.9% and 87.1%, respectively, with a positive predictive value (PPV) of 83.8% and a negative predictive value (NPV) of 75.1%. At a cutoff value of 80 pg/mL, the sensitivity and specificity were 64.4% and 92.4%, respectively, with a PPV of 89% and an NPV of 73%.

### Detection of fungal DNA

In recent years novel molecular methods, notably the amplification of gene sequences unique to fungi by polymerase chain reaction (PCR) assays, have been developed to improve the diagnosis of life-threatening IFIs in high-risk patients. PCR offers the potential for rapid diagnosis. However, due to the absence of a standardized and validated commercial method, the routine use of PCR in the diagnosis of IFI cannot yet be recommended. Real-time techniques combined with automated DNA extraction may, however, allow standardization and reproducibility between centers, and may broaden the clinical applicability of PCR-based diagnosis in the near future ([@b73-tcrm-4-1261]).

### Antibodies against *Candida albicans* germ tubes

A *C. albicans* mannoprotein located on the germ tube cell wall surface is recognized by sera from patients with invasive candidiasis (IC). Recently, an indirect immunofluorescence assay to detect antibodies (CAGTA) against this antigen has been developed and commercialized (*C. albicans* IFA IgG; Vircell Laboratories, Spain) ([@b89-tcrm-4-1261]; [@b115-tcrm-4-1261]). The test has shown an overall sensitivity of 77%--89% and a specificity of 91%--100% and has been useful in the diagnosis of IC in intravenous heroin users, bone marrow transplant recipients and hematological or intensive care patients ([@b117-tcrm-4-1261]). Detection of CAGTA in patients with invasive infections caused by *Candida* spp. other than *C. albicans* (*C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. dubliniensis*, *C. guilliermondii*, and *C. krusei*) may also be positive, although titers are lower than for candidiasis caused by *C. albicans.* In addition, the detection of CAGTA may be useful for the therapeutic monitoring of patients with IC, since the administration of antifungal therapy usually results in decreasing titers of CAGTA ([@b89-tcrm-4-1261]).

In 2006, our group evaluated an immunofluorescence assay for CAGTA detection in a selected population of critically ill patients ([@b158-tcrm-4-1261]). Although there were no differences between CAGTA-positive and -negative patients in terms of age, gender, sequential organ failure assessment score, and renal and hepatic failure, the intra-ICU mortality rate was significantly lower in patients who tested positive for CAGTA (25% vs 65.2%; *P* = 0.025). These results imply that a strategy based on the early determination of CAGTA expression might reduce the ICU mortality rate of patients with risk factors for the development of IC. However, more studies are needed to validate this approach in the critical care setting.

### Combinations of nonculture-based microbiological tools

Recent studies focusing on the combination of nonculture-based microbiological tools have demonstrated improved diagnostic accuracy when combining galactomannan and (1--3)-β-[d]{.smallcaps}-glucan detection ([@b102-tcrm-4-1261]), as well as galactomannan and PCR ([@b84-tcrm-4-1261]; [@b39-tcrm-4-1261]). Additionally, its usefulness for diagnosing and monitoring IC using (1--3)-β-[d]{.smallcaps}-glucan and CAGTA was evaluated in neutropenic adults at high risk. Both tests anticipated the clinical and radiological diagnosis, and the initiation of antifungal therapy in most patients. A combination of both tests improved specificity and positive predictive value to 100% ([@b101-tcrm-4-1261]). These studies suggest that a combination of two tests to detect antigen, antibodies, (1--3)-β-[d]{.smallcaps}-glucan and DNA will be needed to optimize the diagnosis of systemic fungal infections ([@b114-tcrm-4-1261]).

Culture-based microbiological tools
-----------------------------------

Diverse risk factors for IC, including prior *Candida* spp. colonization, could allow the detection of patients that may be potential candidates for preemptive antifungal therapy. Numerous patients are colonized in the ICU but only few subsequently develop systemic candidiasis. Screening for *Candida* colonization assessment is performed routinely in many ICUs. Nevertheless, the value of positive surveillance cultures and of several developed colonization indexes for the prediction of IC and the indication for preemptive antifungal therapy is currently under active investigation ([@b110-tcrm-4-1261]). Recently, a simple scoring system ("*Candida* score") has been evaluated to assist clinicians in differentiating between *Candida* species colonization and proven *Candida* infection in nonneutropenic critically ill patients ([@b70-tcrm-4-1261]).

In conclusion, although substantial progress has been made in the diagnosis of IFIs, no single test has found widespread clinical use. There is a consensus in publications that results obtained from a panel of diagnostic tests in association with blood culture findings and clinical aspects of the patient will likely be the most useful strategy for the early diagnosis of patients with IFIs and the monitoring of therapeutic response.

The laboratory and the empirical antifungal therapy
---------------------------------------------------

In patients at high risk of fungal infection, the administration of empirical antifungal treatment must be considered since a relationship between the delay in the initiation of treatment and in clinical outcome and hospital mortality has been demonstrated ([@b91-tcrm-4-1261]; [@b44-tcrm-4-1261]). Empirical antifungal therapy is defined as the treatment administered to patients who have several risk factors and clinical features for IFIs, when microbiological documentation, species identification or susceptibility data are still not available.

When this treatment is to be established, several factors must be taken into account, such as: 1) the hospital area epidemiology; 2) previous susceptibility data of species isolated in the hospital area; 3) the multicenter surveillance studies to predict the susceptibility patterns of isolates; 4) the potential risk of emergence of fluconazole resistance or appearance of candidiasis due to fluconazole-resistant species among patients receiving fluconazole prophylaxis ([@b1-tcrm-4-1261]); 5) the presence of neutropenia; 6) the underlying patient conditions which can affect the metabolism of the drug; 7) the toxicity of the antifungal agent; and 8) previous experience in fungal treatment. Furthermore, it must be kept in mind that any individual isolate of any species may become resistant to any antifungal agent.

[Table 1](#t1-tcrm-4-1261){ref-type="table"} summarizes the in vitro susceptibility patterns of yeasts and moulds against the most frequently isolated species. These data are representative of those published in numerous in vitro studies.

In summary, as epidemiological data and resistance to antifungal agents depends on characteristics of patients and geographical localization, it is convenient, in all invasive mycoses, to perform both the identification of all isolates at species level and the antifungal susceptibility tests to identify the local epidemiology so as to apply the most appropriate empirical therapy in each institution.

Prophylaxis, empirical, pre-emptive or targeted therapy, which is the best in critically ill patients?
======================================================================================================

Approximately 10.4% of infections in an ICU are related to *Candida* spp. with the majority being nosocomial ([@b3-tcrm-4-1261]). However, this rate could be underestimated due to the fact that at least 4% of critically ill patients who die in an ICU present an unexpected fungal infection during postmortem examination ([@b31-tcrm-4-1261]). Furthermore, ICU admission itself has become an independent risk factor for the development of a *Candida* spp. infection ([@b116-tcrm-4-1261]; [@b144-tcrm-4-1261]).

*Candida* infections are associated with a significant mortality rate, particularly among critically ill patients ([@b69-tcrm-4-1261]). The crude mortality rate of these infections has been estimated at 40%--75%, and the mortality rate attributable to candidemia at 25%--38% ([@b93-tcrm-4-1261]; [@b106-tcrm-4-1261]; [@b144-tcrm-4-1261]; [@b4-tcrm-4-1261]). A review of matched cohort and case-control studies has examined the mortality rate that could be linked to candidemia ([@b38-tcrm-4-1261]). The data suggested that candidemia is indeed associated with a considerable mortality rate that can be attributed to the infection itself.

In recent years, the species of *Candida* that result in candidemia have shifted from *C. albicans* to non-*C. albicans* (NCA). Approximately half of the reported cases of candidemia are now caused by NCA species ([@b107-tcrm-4-1261]; [@b144-tcrm-4-1261]; [@b4-tcrm-4-1261]), and several publications have indicated that these cases have a worse prognosis than those caused by *C. albicans* ([@b10-tcrm-4-1261]; [@b63-tcrm-4-1261]; [@b90-tcrm-4-1261]; [@b30-tcrm-4-1261]). This increase has been attributed to the use of fluconazole prophylaxis ([@b123-tcrm-4-1261]). Other adverse outcome predictors described in candidemia episodes are the length of ICU stay, renal failure, thrombocytopenia, hematologic malignancy, and the need for mechanical ventilation or inotropic support ([@b10-tcrm-4-1261]; [@b4-tcrm-4-1261]). In a Spanish multicenter study involving ICU patients in 28 hospitals, an Acute Physiology and Chronic Health Evaluation (APACHE) II score of \>20 at the time of candidemia was associated with a higher mortality rate ([@b93-tcrm-4-1261]), whereas early treatment with antifungal medication and the removal of central venous catheters were protective against death ([@b93-tcrm-4-1261]; [@b4-tcrm-4-1261]). Furthermore, inadequate empiric antibiotic treatment it is associated with IFIs and a worse prognosis ([@b100-tcrm-4-1261]). Two reports have demonstrated a strong association between a delay in the start of antifungal therapy and an increase in hospital mortality rates ([@b91-tcrm-4-1261]; [@b44-tcrm-4-1261]); thus, it is necessary to recognize that time is of the utmost importance when considering the therapy of patients who are at risk for IFIs.

Prophylaxis of *Candida* infections in ICU
------------------------------------------

The implementation of targeted antifungal prophylaxis has been shown to be effective in certain ICU settings ([@b17-tcrm-4-1261]). Results from controlled randomized trials ([@b36-tcrm-4-1261]; [@b104-tcrm-4-1261]; [@b43-tcrm-4-1261]) support the efficacy of azole prophylaxis in nonneutropenic high-risk ICU patients, diminishing the incidence of *Candida* infection but not mortality.

Three recently published meta-analysis have tried to evaluate the impact of fluconazole prophylaxis on the incidence of fungal infections and on mortality among critically ill surgical patients ([@b26-tcrm-4-1261]; [@b125-tcrm-4-1261]; [@b113-tcrm-4-1261]). The meta-analysis by [@b125-tcrm-4-1261] demonstrated that prophylactic fluconazole administration in surgical ICU patients appears to successfully decrease the rate of mycoses, but this strategy does not improve survival. The second meta-analysis by [@b26-tcrm-4-1261] showed that patients who received azole prophylaxis (fluconazole and ketoconazole) experienced a 80% relative risk reduction in candidemia, 31.5% relative risk reduction in overall mortality, and 79.4% reduction in mortality attributable to *Candida* infections. Finally, [@b113-tcrm-4-1261] reported reduction of the IFI incidence rate by about 50% and overall mortality by about 25%.

Currently, because of the potential for both resistance and emergence of non-*albicans* isolates, clinicians must properly consider these issues when evaluating fluconazole prophylaxis in ICU, although the meta-analyses published by [@b113-tcrm-4-1261] describes above showed no evidence of epidemiological shifts after fluconazole prophylaxis.

In addition, it has been criticized that all controlled randomized trials included into the metaanalyses by Playford and Cruciani and colleagues were limited by their monocentric design and each of them focused on a group of clinically distinctive patients.

Under these circumstances, prophylactic use of fluconazole in high risk ICU patients cannot be generally recommended, but should be restricted to patients with multiple risk factors for developing IC, for instance as Playford recommend, if the cumulative incidence of IC in a certain subpopulation of the ICU approaches or exceeds 10%, in spite of active prevention, prophylaxis should be initiated. Using this approach, the number needed to treat to prevent one case of IC ranges between 17 (for a risk of 11%) and nine patients (for a risk of 20%). The subgroups of patients who might most benefit from prophylaxis in ICU may be patients with upper gastrointestinal perforation ([@b104-tcrm-4-1261]; [@b43-tcrm-4-1261]), patients with heavy *Candida* colonization ([@b110-tcrm-4-1261]), and patients with severe acute pancreatitis ([@b29-tcrm-4-1261]).

Empirical antifungal treatment in ICU
-------------------------------------

### Assessing risk

The early identification of risk factors for the development of candidemia such as peritonitis, abdominal surgery, previous administration of broad-spectrum antibiotics, parenteral nutrition, multiple lumen catheters, prior *Candida* spp. colonization, renal replacement therapy, and mechanical ventilation ([@b106-tcrm-4-1261]; [@b13-tcrm-4-1261]; [@b6-tcrm-4-1261]), has become the cornerstone of empiric treatment of fungal infections in the ICU setting in order to reduce the high mortality rate associated with these infections ([@b58-tcrm-4-1261]; [@b45-tcrm-4-1261]).

### The Ostrosky-Zeichner prediction rule

In a multicenter retrospective setting, [@b96-tcrm-4-1261] created a prediction rule for IC. The rule was obtained through analysis of a group of 2890 patients, in which incidence of IC was 3% (88 cases). Statistical modeling revealed a particularly high risk for patients under systemic antibiotic treatment (days 1--3) or with indwelling central venous catheter (days 1--3) and at least two of the following factors: total parenteral nutrition (days 1--3), any dialysis (days 1--3), any major surgery (days --7--0), pancreatitis (days --7--0), any use of steroids (days --7--3), or use of other immunosuppressive agents (days --7--0). The rule was associated with a sensitivity of 34%, a specificity of 90%, and a PPV and a NPV of 1% and 97%, respectively. This rule applies to approximately 10% of patients who stay in the unit for \>4 days, and approximately 10% of patients to whom this rule is applied will develop proven or probable IC. In this study, patients with any combination of diabetes mellitus, new-onset hemodialysis, use of total parenteral nutrition, or receipt of broad-spectrum antibiotics had an IC rate of 16.6%. This compared with a rate of 5.1% in patients who lacked these characteristics (*P* = 0.001). Fifty-two percent of patients who stayed in the ICU for ≥4 days met this rule, and the rule captured 78% of patients who eventually developed IC.

### The *Candida* score

A Spanish group reported on the development of a bedside scoring system that allows early antifungal treatment when candidemia is suspected in nonneutropenic ICU patients ([@b70-tcrm-4-1261]). This "*Candida* score" is based on the predictive value of previously reported risk factors. Using a logistic regression analysis and adjusting for possible confounding variables, the authors found several factors to be independently associated with a greater risk for proven candidal infection. The scores for the individual factors were: parenteral nutrition (+0.908), prior surgery (+0.997), multifocal *Candida* colonization (+1.112), and severe sepsis (+2.038). The authors concluded that a "*Candida* score" of \>2.5 could accurately select patients who would benefit from early antifungal treatment (sensitivity 81%, specificity 74%).

Pre-emptive antifungal treatment in the ICU
-------------------------------------------

Poor outcomes are, in part, associated with difficulties in establishing the microbiologic diagnosis at an early stage of infection. Blood culture results are positive in only 50% of invasive *Candida* and *Fusarium* infections, and are very rarely positive in cases of IA. Cultures of bronchoalveolar lavage fluid or brushing specimens are positive in \<50% of subjects with invasive pulmonary aspergillosis. Finally, positive cultures of specimens from nonsterile body sites may be related to either colonization or infection, and distinguishing between these can be difficult. Nonculture-based diagnostic tests may provide a useful adjunct to these more traditional approaches.

### Corrected colonization index

[@b110-tcrm-4-1261] assessed the efficacy of a pre-emptive antifungal therapy in preventing proven candidiasis in critically ill surgical patients, using a corrected colonization index (CCI) (ratio of highly positive samples to the total numbers of samples cultured) to measure the intensity of *Candida* mucosal colonization. Patients with a CCI value of ≥0.4 received early pre-emptive antifungal therapy with fluconazole, and the incidence of ICU-acquired proven candidiasis decreased significantly from 2.2 to 0%. However, it is possible that the overload of samples sent to the microbiology laboratory could limit the widespread use of this approach.

Targeted treatment of invasive candidiasis in the ICU
-----------------------------------------------------

The best first-line treatment for candidemia in critically ill patients remains controversial. Clinical studies have shown that amphotericin B (AmB), fluconazole, echinocandins, and voriconazole have similar efficacy in the treatment of *Candida* bloodstream infections ([@b120-tcrm-4-1261]; [@b109-tcrm-4-1261]; [@b88-tcrm-4-1261]; [@b66-tcrm-4-1261]). In accordance with the last IDSA guidelines ([@b98-tcrm-4-1261]), many experts favor initial treatment with AmB in severely ill or clinically unstable patients; although the recent published Swiss guidelines for fungal infections ([@b40-tcrm-4-1261]) do not support this statement. However, its renal toxicity could present a serious problem in these individuals, which may often preclude its use as first-line therapy ([@b9-tcrm-4-1261]; [@b12-tcrm-4-1261]).

While the triazole, fluconazole, may be selected on the basis of its efficacy and safety ([@b120-tcrm-4-1261]; [@b109-tcrm-4-1261]), the increasing frequency of patients infected with *Candida* strains that are resistant to this drug highlight the need for initial treatment with a broader-spectrum agent, at least until the *Candida* spp. is identified, in order to avoid inadequate antifungal treatment and an associated increased mortality rate ([@b157-tcrm-4-1261]). Results from the first randomized, prospective, multicenter study in nonneutropenic patients with candidemia who were treated with either voriconazole alone or AmB deoxycholate followed by fluconazole have demonstrated equivalence of these two regimens with regard to efficacy and mortality rates ([@b66-tcrm-4-1261]). Response rates were similar in the voriconazole and AmB/fluconazole arms; however, for *C. tropicalis* infection, the response rate was significantly higher in the group treated with voriconazole, despite in vitro susceptibility of these strains to AmB. These results can be easily applied to critically ill patients as approximately half of the patients included in the study were admitted to an ICU. The only limitation to the use of intravenous voriconazole in these patients could be the accumulation and toxicity of its excipient (cyclodextrin) in severe renal dysfunction, although there are no data regarding this concern in patients undergoing renal replacement therapy.

Published reports suggest that caspofungin is equivalent in efficacy to standard therapy with AmB in the treatment of *Candida* infections ([@b88-tcrm-4-1261]). [@b88-tcrm-4-1261] compared caspofungin to AmB in the treatment of IC in nonneutropenic (n = 200) and neutropenic patients (n = 24). Caspofungin was as efficacious as AmB, with favourable response rates of 73.4% and 61.7%, respectively. Micafungin has become the second available echinocandin approved for use in the USA and Japan for the treatment of esophageal candidiasis and prophylaxis in subjects with neutropenia ([@b20-tcrm-4-1261]). Recently, two different studies have been published for invasive candidiasis ([@b67-tcrm-4-1261]; [@b99-tcrm-4-1261]). In these studies, micafungin was as effective as liposomal AmB ([@b67-tcrm-4-1261]) or caspofungin ([@b99-tcrm-4-1261]) as first-line treatment of candidemia and IC and caused fewer adverse events than liposomal AmB. Finally, anidulafungin is the only antifungal compound that has been able to demonstrate superiority over fluconazole in IC ([@b118-tcrm-4-1261]), although we must be cautious with the results presented as the study involved was powered a priori for equivalency. However, anidulafungin's efficacy and safety profile could indicate that it should be readily considered as a first-line option for the treatment of IC.

In the last years, some publications have shown a shift toward the use of antifungal drugs other than fluconazole due to the increasing number of non-*C. albicans* (NCA) isolates ([@b123-tcrm-4-1261]; [@b157-tcrm-4-1261]). Consequently, the application of an early de-escalation therapy in critically ill patients with fungal infection should be recommended ([@b157-tcrm-4-1261]). For this reason, voriconazole (due to its broad spectrum and good profile in the ICU setting), caspofungin, anidulafungin and micafungin (particularly in renal dysfunction) could be attractive options in critically ill patients. Finally, the choice of antifungal drug must be based on the individual characteristics of the patient, and particularly focus on the presence of renal or hepatic failure, hemodinamic instability and possible interactions with other drugs. The presence of hemodynamic instability is a mayor factor for choosing empirical therapy. This fact has been considered by the recent guidelines published enhancing a tailored therapy (de-escalation) especially with severe sepsis or septic shock ([@b98-tcrm-4-1261]; [@b40-tcrm-4-1261]). All these guidelines heavily recommend, including last ongoing IDSA guidelines, the use of echinocandins in noneutropenic patients with IC when hemodynamic inestability was present. The high rate of clinical success of these agents in candidemia, their low toxicity, their excellent safety profile and their broad spectrum against non-*albicans* spp. makes this recommendation feasible. A recent publication has corroborated the use of caspofungin in critically ill patients ([@b32-tcrm-4-1261]).

In conclusion, IFIs, especially in the critical care setting, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions. [Table 2](#t2-tcrm-4-1261){ref-type="table"} summarizes the antifungal therapy strategies in ICU patients.

Prophylaxis, empirical, pre-emptive or targeted therapy, which is the best in hematological patients?
=====================================================================================================

Hematological patients are prone to IFI since most of them receive myelotoxic chemotherapy and usually have more than one of well-known risk factors for IFI (eg, long-lasting neutropenia, older age, active cancer, corticosteroid therapy, administration of broad spectrum antibiotics, allogeneic HSCT, central venous catheter, organ dysfunction). These patients are usually polymedicated and are thus exposed to harmful drug interactions. Furthermore, it is important to emphasize that the same individual patient will be at risk at several time points through the entire treatment plan for his/her underlying disease. Thus, the planned antineoplastic treatment should be kept in mind when designing antifungal strategies for hematological patients.

Prophylaxis of IFI in hematological patients
--------------------------------------------

Historically, outcomes for IFI have been disappointing and associated with a high mortality rate. Because of this, prophylaxis has been the first option to consider in hematological patients. Since the early 90's, fluconazole prophylaxis has reduced infections caused by *Candida* spp. but dramatic changes in the epidemiology of IFI have occurred, with *Aspergillus* spp. and NCA species becoming increasingly common. These changes have affected the selection of antifungals for first-line or prophylactic use, as not all agents have the spectrum of activity required. At this point, it should be noted that evidence based recommendations are to be interpreted with caution and so we should always consider the moment when they were formulated. For example, benefit of antifungal prophylaxis with fluconazole (400 mg/day) in allogeneic HSCT recipients continues to be an A-I recommendation but today *C. albicans* is not longer the predominant pathogen in this setting. However, newer azoles have the potential to provide protection against mould infections that are difficult to treat once they occur. Two large randomized, fluconazole- or itraconazole-based controlled clinical trials in acute leukemia patients ([@b24-tcrm-4-1261]) and in HSCT recipients with graft-versus-host disease (GVHD) ([@b146-tcrm-4-1261]) have demonstrated the efficacy of oral posaconazole (200 mg thrice daily) for reducing invasive mould infections. Ideally prophylaxis should usually be initiated in parallel with the administration of cytotoxic therapy in order to ensure a protective effect at the time of maximal neutropenia and intestinal epithelial damage, but concerns over drug interactions make advisable to start triazole-based prophylaxis after the administration of cytotoxic therapy, especially in HSCT recipients. The ability to switch from the oral to an intravenous formulation for the same antifungal product in the setting of severe oral mucositis is an advantage. Both oral solution and intravenous formulation of itraconazole are suitable for prophylaxis in high-risk patients, but compliance with the oral solution is poor ([@b79-tcrm-4-1261]). A preliminary report of a large trial to assess prophylactic voriconazole in allogeneic HSCT recipients (oral or IV 200 mg BID) was recently presented ([@b153-tcrm-4-1261]). Prophylaxis with micafungin ([@b148-tcrm-4-1261]) and caspofungin ([@b80-tcrm-4-1261]) have been studied at daily IV doses of 50 mg but echinocandins are preferred in the clinical practice for therapy instead of prophylaxis. The end of prophylaxis should be dictated by the termination of the specific risk. Mould-active prophylaxis may require administration into the late post-engraftment period in allogeneic HSCT for those patients with higher risk due to acute or chronic GVHD requiring augmented immunosuppressive therapy ([@b79-tcrm-4-1261]; [@b146-tcrm-4-1261]). Finally, the use of aerosolized lipid-based formulations of AmB may prove to be useful as prophylaxis for mould infection in the respiratory tract, the major portal of entry of fungal conidia ([@b121-tcrm-4-1261]). The combination of nebulized AmB with fluconazole is an interesting approach to avoid drug interactions (eg, in patients receiving vinca alkaloids).

Empirical therapy of IFI in hematological patients
--------------------------------------------------

For lower risk patients or when IFI is suspected in patients receiving prophylaxis, empirical antifungal therapy is often employed following a predefined duration of fever. During the early 1980s one quarter to one third of severely neutropenic cancer patients with persistent or relapsing fever despite broad-spectrum antibacterial therapy developed IFI. Empirical AmB deoxycholate reduced the incidence of IFI and overall mortality by 50%--80% and 23%--45%, respectively. Fever is a poorly predictive surrogate upon which to base an intervention such as empirical antifungal therapy ([@b28-tcrm-4-1261]). Although a substantial number of leukemia patients and HSCT recipients are given empirical antifungal therapy, proven IFI occurs in only 2% to 15% ([@b62-tcrm-4-1261]; [@b15-tcrm-4-1261]; [@b145-tcrm-4-1261]; [@b24-tcrm-4-1261]) suggesting that the current guidelines ([@b54-tcrm-4-1261]) based upon persistent neutropenic fever are significantly flawed and may result in unjustifiable excess treatment-related toxicities and resource expenses ([@b28-tcrm-4-1261]).

Currently, caspofungin and liposomal AmB are the first-line option for treating patients with febrile neutropenia ([@b149-tcrm-4-1261], [@b151-tcrm-4-1261]). The role of voriconazole as an empirical treatment for patients with febrile neutropenia remains unresolved, and in fact, voriconazole is currently not licensed for this indication. The results of a large, international, multicenter, randomized study that compared voriconazole with liposomal AmB for the empirical treatment of febrile neutropenic patients have been controversial ([@b150-tcrm-4-1261]). According to the predefined end point of this study (noninferiority), voriconazole did not achieve this goal relative to liposomal AmB; the overall success rates were 26% and 30.6%, respectively. Breakthrough fungal infections occurred in eight patients (1.9%) in the voriconazole group compared with 21 patients (5%) in the liposomal AmB group (*P* = 0.02). However, more patients died in the voriconazole group and a claimed significant reduction in the number of breakthrough fungal infections disappeared when patients arbitrarily excluded from analysis by the trial authors were included ([@b61-tcrm-4-1261]).

Continuous infusion administration AmB has been proposed over the past few years, claiming it could reduce the risk of nephrotoxicity associated to this agent. The preliminary results of an open study, including 80 neutropenic patients during 4 hour infusion versus continuous infusion, suggest more advantages for continuous infusion. A significantly lower incidence in reactions related with the infusion was found in the case of continous administration, which also favored the creatinine clearance values ([@b37-tcrm-4-1261]). Another cohort study on 81 febrile neutropenic hematological patients with a higher IFI risk, evaluated the administration of AmB in intermittent infusion during 4h, compared to a continuous infusion ([@b103-tcrm-4-1261]). Kidney failure was seen in 45% and 10% of the patients, respectively (OR 0.14; IC 95% 0.04--0.5; *P*\<0.001). The result was similar in patients with allogeneic transplant and in those which were given other nephrotoxic drugs. A multivariate logistic regression showed that the continuous infusion was the only variable significantly associated to kidney failure, with a protective effect.

Nevertheless, the use of continuous infusion is still controversial. Whilst some authors defend this strategy before opting for lipid or liposomic formulations ([@b60-tcrm-4-1261]; [@b122-tcrm-4-1261]), others do not consider it totally acceptable because of limited experience. [@b5-tcrm-4-1261], when repeating the experience provided by [@b103-tcrm-4-1261], found no significant advantages between intermittent and continuous infusion in patients with a high IFI risk.

Pre-emptive therapy of IFI in hematological patients
----------------------------------------------------

A more refined approach is pre-emptive therapy where treatment is only initiated upon positive identification of a surrogate marker of infection in combination with clinical and radiological signs. This pre-emptive therapy will subject fewer patients to toxic and expensive treatments. The interest in this strategy is based upon the observation that early detection is associated with better outcomes. A study in acute leukemia patients receiving fluconazole prophylaxis examined an algorithm-based pre-emptive approach based upon serial diagnostic testing and clinical monitoring ([@b74-tcrm-4-1261]). Only patients with ≥2 positive serum GM assays or CT and or bronchoscopic evidence for mould infection received antifungal therapy. A total of 41 of 117 febrile neutropenic episodes (35%) had persistent neutropenic fever; however, only 9 patients (22% of the 41 persistent neutropenic fevers; 8% of the original febrile neutropenic episodes) satisfied the pre-defined criteria for antifungal therapy. Despite these promising observations, the appearance of a clinical or radiological marker such as a suggestive nodular pulmonary infiltrate on computerized thoracic tomography in a high-risk patient will compel the anxious physician to initiate antimould therapy independent of molecular markers. Pre-emptive strategies are intellectually attractive because they combine in an elegant manner newer diagnostic tools in order to give antifungal therapy only to patients who really deserve it. However, in the real world, they are difficult to carry out. Furthermore, nonculture methods such is serum GM assay lose diagnostic power if an anti-mould prophylaxis is given, which in turn will be given to higher risk patients. Thus pre-emptive therapy based on sensitive diagnostic non-culture methods needs further validation in larger randomized trials before becoming a standard.

Targeted therapy of IFI in hematological patients
-------------------------------------------------

Targeted therapy is used in patients with confirmed IFI. Again hematological patients deserve especial consideration as they are commonly at high risk of hemorrhagic complications that render them unfit for aggressive diagnostic procedures including biopsies. Therefore many suspected cases will be diagnosed as probable IFI at the most.

A study comparing voriconazole to conventional AmB in 277 patients ([@b51-tcrm-4-1261]) demonstrated higher response rates among voriconazole recipients (52.8% versus 31.6%), a 67% improvement. Patients with early lesions characterized by pulmonary nodules with halos had higher treatment response rates (52.4% versus 29.1%) ([@b46-tcrm-4-1261]). Moreover, a survival advantage for voriconazole recipients was observed (70.8% compared to 57.9%, *P* = 0.024). Despite this, response among allogeneic HSCT recipients remained suboptimal (32.4% for voriconazole versus 13.3% for conventional AmB). A study of dose-intense (10 mg/kg/d for 14 days followed by 3 mg/kg/d vs 3 mg/kg/d) of liposomal AmB as primary therapy for IA demonstrated similar response rates (46% vs 50%, respectively), but more nephrotoxicity (31% versus 14%), hypokalemia (30% versus 16%), and higher mortality in the dose-intense group (41% versus 28%) ([@b23-tcrm-4-1261]). Based on this experience, the value of dose-intensity for IA appears limited.

Poor response rates for primary and salvage monotherapy therapy for IFI and the availability of increasingly safer agents with differing mechanisms of action have prompted hematologists to use early combination therapy. Arguments for considering combination therapy include enhanced fungal killing (synergy), an enhanced spectrum of activity, prevention of development of resistance, and reduction of drug-related toxicities ([@b64-tcrm-4-1261]). Favorable responses were observed among HSCT patients failing polyene-based therapy for IA with a combination of voriconazole and caspofungin compared to voriconazole monotherapy ([@b78-tcrm-4-1261]). Recently, a French multicenter randomized study comparing combination therapy with liposomal AmB (3 mg/kg/d) plus caspofungin (70 mg day 1 and 50 mg/d thereafter) versus high-dose liposomal AmB monotherapy (10 mg/kg/d) for primary treatment of IA was published ([@b16-tcrm-4-1261]). A favorable overall response was observed in 67% combination therapy recipients compared to 27% high-dose therapy recipients (*P* = 0.028). The results of this small pilot, representing the first prospective study of combination therapy in IA, are encouraging but need confirmation. Combination antifungal therapies are expensive and potentially toxic and there are limited well-designed randomized-controlled trials to guide the practicing clinician faced with managing these problems.

In conclusion, risk-adapted prophylaxis is the best option in hematological patients. [Table 3](#t3-tcrm-4-1261){ref-type="table"} resumes the antifungal therapy strategies in these patients.

Prophylaxis, empirical, pre-emptive or targeted therapy, which is the best in solid organ transplant recipients (SOT)?
======================================================================================================================

Renal, liver, heart, and lung transplantation are now considered to be the standard therapeutic interventions in patients with end-stage organ failure. The use of newer more potent immunosuppressive regimens as well as widespread use of antifungal drugs has changed the landscape of fungal infections. The incidence of invasive mycoses following SOT ranges from 5% to 42% depending on the organ transplanted ([@b77-tcrm-4-1261]; [@b128-tcrm-4-1261]; [@b139-tcrm-4-1261]). Fungal infections in SOT recipients continue to be a significant cause of morbidity and mortality. The clinical and epidemiological characteristics of IFIs in recipients of nonpulmonary solid organ transplantation (NP-SOT) are very different from which occurs in the patients with lung transplantation (LT) or HSCT. The incidence of invasive mycoses varies with type of SOT, though *Candida* spp. and *Aspergillus* spp. account for most IFI in SOT recipients ([@b126-tcrm-4-1261]). Liver transplant recipients have highest reported incidence of *Candida* infections while LT recipients have highest rate of *Aspergillus* infections ([@b129-tcrm-4-1261]; [@b134-tcrm-4-1261]; [@b137-tcrm-4-1261]; [@b140-tcrm-4-1261]). Recent epidemiological studies suggest the emergence of resistant strains of *Candida* as well as mycelial fungi other than *Aspergillus* in these patients. Moreover, significant percentages of fungal infections are occurring late in the course of transplantation. SOT recipients also are at risk for *Cryptococcus* infections ([@b130-tcrm-4-1261]) and reactivation of endemic mycoses such as histoplasmosis and coccidiomycosis.. Emergence of newer and more potent antifungal agents with lower toxicity potentially changes the concept of antifungal prophylaxis ([@b147-tcrm-4-1261]; [@b83-tcrm-4-1261]).

Prophylaxis and pre-emptive therapy of IFI in solid organ transplant patients
-----------------------------------------------------------------------------

Several prophylactic strategies with antifungal drugs have been reported to result in a decreased incidence and mortality of fungal disease in LT recipients ([@b25-tcrm-4-1261]; [@b57-tcrm-4-1261]; [@b76-tcrm-4-1261]); however, there has not been a uniform approach, data are limited, and besides there is a considerable variation in anti-fungal prophylaxis practices among LT centres throughout the world. The majority of LT programs are using universal antifungal prophylaxis in the postoperative period; about 30% use a pre-emptive approach for patients with pre- and/or post-transplant fungal airway colonization. As the antifungal agent used as the duration of prophylaxis varies substantially from center to center ([@b57-tcrm-4-1261]). It is clear that there is considerable uncertainty to which approach (prophylaxis or pre-emptive therapy) is most appropriate, which agent is the best, and what duration of prophylaxis or pre-emptive therapy is needed. Antifungal prophylaxis in LT recipients should be taken into account the incidence of colonization, anastomoses healing, chronic rejection, and the time of LT, thus providing a rationale for the duration of therapy.

To prevent invasive pulmonary aspergillosis, multiple strategies and antifungal drugs have been utilized such as oral itraconazole, voriconazole or aerosolized AmB used alone or in combination. Aerosolized medication regimens are an attractive option, as drug interactions and systemic toxicities are likely to be limited ([@b33-tcrm-4-1261]). Lipid preparations of AmB appear to be ideal for inhalational administration; however, there are not rigorous pharmacokinetic studies in LT recipients, to determine the appropriate dose and schedule of their administration. Monforte and colleagues have demonstrated that aerosolized AmB and lipid preparations of AmB are safe and achieve high concentrations in BAL fluid for the first 24 hours and 14 days, respectively, following nebulization ([@b87-tcrm-4-1261], [@b86-tcrm-4-1261]). These lipid formulations let a delayed administration (every 7--14 days), which is rebounded and better accomplished by patient. Several centers have reported on the safety of aerosolized AmB with a variety of dosing regimens ([@b119-tcrm-4-1261]; [@b18-tcrm-4-1261]; [@b87-tcrm-4-1261]), and others with aerosolized AmB lipid formulations ([@b97-tcrm-4-1261]; [@b34-tcrm-4-1261]; [@b71-tcrm-4-1261]). Our group has used aerosolized AmB as part of the post-LT protocol since 1994 ([@b18-tcrm-4-1261]). Since three years ago we also are using AmB lipid complex, with the same respiratory tolerability and safety that aerosolized AmB, but AmB lipid complex results more comfortable for long periods of time (50 mg inhaled/weekly), and patients have better adherence to treatment. Recently, in vitro suitability of caspofungin for aerosol administration has been characterized ([@b156-tcrm-4-1261]). Caspofungin solution appeared to have physicochemical and aerodynamic characteristics suitable for aerosolization. However, further in vivo testing is warranted. Although the incidence of IFI seems to be reduced with aerosolized AmB prophylaxis, the efficacy of this approach has not been determined in a large prospective clinical trial. Furthermore, without detectable levels of AmB in the circulation, extrapulmonary fungal infections may not be prevented by this strategy. Besides, it is important to take into consideration the type of delivery systems used for inhaled drugs ([@b21-tcrm-4-1261]; [@b47-tcrm-4-1261]). In addition, contamination of the nebulization systems used in the prophylaxis with AmB nebulized in LT has been described ([@b87-tcrm-4-1261]). The contamination of the nebulizing systems may be the origin of respiratory infections and it is frequent when no strict cleaning and disinfection protocol is followed.

In conclusion, aerosolized antifungal therapy is a promising route of drug delivery for pulmonary aspergillosis due to attainment of high localized concentrations ([@b85-tcrm-4-1261]; [@b138-tcrm-4-1261]).

Respect to oral prophylaxis, recently a study that examined the efficacy and toxicity of a strategy of universal *de novo* antifungal prophylaxis with voriconazole compared to targeted antifungal prophylaxis has been published ([@b55-tcrm-4-1261]). The main finding of this study was that the overall rate of IA at 1 year decreased to 1.5% with universal voriconazole prophylaxis as compared to 23.5% with a targeted prophylaxis strategy. Interestingly, the rate of *Candida* colonization, particularly non-*albicans* spp. in the voriconazole group was significantly higher. In the voriconazole prophylaxis cohort, 27% of the LT recipients had normal liver enzymes throughout the course of the study. The main handicap of this azole therapy is the strong interaction with immunosuppressors that obliges to monitoring calcineurin inhibitors to avoid toxicity or rejection. Other interesting finding was that universal voriconazole prophylaxis did not increase the rate of non-*Aspergillu*s fungal infections (specially, zygomycosis).

Available echinocandins (caspofungin, micafungin, anidulafungin) may have an important role in prophylaxis because of their antifungal profile, pharmacokinetics and security; however, they are expensive and need intravenous administration.

Another question is how long should be prophylaxis maintained? The majority of centers agree to apply universal prophylaxis during first period post transplant (3 months) after this time, each center use a tailored prophylaxis. Besides, it is recommended to use nebulized antifungal prophylaxis and/or preemptive therapy with antifungal agents (voriconazole) in patients with chronic rejection and respiratory samples positive for *Aspergillus*, even without clinical or radiological signs, mainly in single LT patients due to the high risk of IA ([@b137-tcrm-4-1261]). This preemptive treatment should last for at least 6 months, the time period over which colonization has been shown to precede disseminated infection ([@b131-tcrm-4-1261]) and in some cases for life. [Table 4](#t4-tcrm-4-1261){ref-type="table"} shows antifungal therapy strategies in LT patients.

Due to the difficulty in obtaining a proven diagnosis of IFI, empiric and pre-emptive therapy plays an important role in NP-SOT patients ([Table 5](#t5-tcrm-4-1261){ref-type="table"}) ([@b68-tcrm-4-1261]; [@b14-tcrm-4-1261]). As it is mentioned in [Table 6](#t6-tcrm-4-1261){ref-type="table"}, some of NP-SOT recipients have additional risk factors that increases the probability of suffer an IFI caused by *Aspergillus* spp. ([@b35-tcrm-4-1261]; [@b129-tcrm-4-1261]; [@b133-tcrm-4-1261], [@b134-tcrm-4-1261]). For this reason, the incorporation of a strategy of antifungal prophylaxis adapted-to-risk is accepted and high risk patients need to be identified in order to prevent the development of the disease ([@b112-tcrm-4-1261]; [@b19-tcrm-4-1261]; [@b48-tcrm-4-1261]).

Since the IFI risk is lower in the cardiac and kidney recipient patients, we will make reference mainly to patients with orthotopic liver transplantation (OLT) as paradigm of the indication of antifungal prophylaxis in NP-SOT patients. However, prophylaxis of candidiasis in SOT recipients is a challenging topic. Strategies to prevent IC should be based on institutional trends and, when appropriate, should target high-risk patients only ([@b127-tcrm-4-1261]). Only a few well-designed studies have been conducted and all of the controlled trials were performed in liver transplant recipients. Oral prophylaxis with nonabsorbable antifungal agents (nystatin, clotrimazole, AmB) has shown inconsistent results ([@b152-tcrm-4-1261]; [@b7-tcrm-4-1261]; [@b52-tcrm-4-1261]; [@b49-tcrm-4-1261]). Two randomized controlled trials have shown the efficacy of fluconazole in the prophylaxis of IC. In one study, comparing fluconazole 100 mg/day for the first 4 weeks following liver transplantation to oral nystatin, fluconazole was associated with a reduction in *Candida* colonization and superficial infections, as well as a trend toward reduction of invasive infections ([@b72-tcrm-4-1261]). In a randomized, placebo-controlled study, fluconazole 400 mg/day for 10 weeks after liver transplantation prevented most types of *Candida* infection, except those caused by *C. glabrata* and *C. krusei*. In another double blind randomized control trial itraconazole decreased the rate of fungal infection from 24% to 4% in liver transplant recipients ([@b124-tcrm-4-1261]). A recently published meta-analysis showed that antifungal prophylaxis in liver transplant recipients significantly reduced the total episodes of superficial and IFI caused by yeasts (at least for *C. albicans*), as well as mortality attributable to fungal infections; however, it did not affect overall mortality or the need for empirical antifungal treatment ([@b27-tcrm-4-1261]). Compared to controls, patients receiving prophylaxis experienced a higher proportion of episodes of *Candida* non-*albicans* infections. Prophylactic strategies against invasive *Candida* infections should be reassessed periodically because risk factors continue to evolve in liver transplant recipients ([@b56-tcrm-4-1261]).

Antifungal prophylaxis to prevent IA remains an unsettled issue in NP-SOT. To date, no prospective randomized studies have demonstrated that antifungal prophylaxis prevents IA in OLT. A recent meta-analysis of antifungal prophylaxis in OLT demonstrated no beneficial effect on IA. Observational studies, however, suggest that targeted prophylaxis with lipid formulations of AmB may be effective in preventing IA in high-risk OLT recipients ([@b135-tcrm-4-1261]; [@b41-tcrm-4-1261]). Lipid formulations of AmB at a dose of 5 mg/kg/day have been shown to be efficacious in reducing IFI in high-risk OLT recipients on renal replacement therapy, although there was no reduction in mortality. A study of universal prophylaxis with cumulative doses of 1--1.5 g of liposomal or lipid complex AmB showed a reduction in the incidence of IA, which was most significant among patients receiving renal replacement therapy (0% vs 32% on controls). However, low doses of lipid formulations of AmB failed to prevent IA ([@b143-tcrm-4-1261]).

The efficacy of the antifungal prophylaxis oral solution of itraconazole as has been assessed in two reports on OLT recipients. A randomized, controlled trial of itraconazole in an oral solution (200 mg every 12 h) versus intravenous or oral fluconazole (400 mg every 24 h) documented no significant difference in the incidence of IA ([@b154-tcrm-4-1261]).

On the other hand, the Spanish group GESITRA has communicated recently the preliminary results of a prospective, noncomparative, open label trial on antifungal prophylaxis with caspofungin in high-risk OLT recipients ([@b42-tcrm-4-1261]). Overall, caspofungin prophylaxis was successful in 87.8% of the patients. These results suggest promise for the prophylactic use of echinocandins in high risk OLT.

However, it is controversial the election of antifungal agent for prophylaxis in these patients. The high cost and the need of parenteral infusion limits the use of lipid formulations of AmB and caspofungin. Despite in vitro data suggesting that caspofungin in combination with calcineurin or TOR-inhibitors may have enhanced activity against *Aspergillus*, breakthrough infections in patients on caspofungin have been noted ([@b65-tcrm-4-1261]). The recommendations for prophylaxis against *Aspergillus* in OLT are a lipid formulation of AmB, voriconazole or caspofungin, with a duration of 3--4 weeks or until resolution of risk factors. In heart transplant recipients routine antifungal prophylaxis is not warranted, but in patients deemed to be at high risk ([Table 6](#t6-tcrm-4-1261){ref-type="table"}), itraconazole at 400 mg daily administered orally from day 5 after transplantation for 3 to 6 months is associated with a significantly lower incidence of IA ([@b92-tcrm-4-1261]).

Randomized studies in high-risk patients are needed to determine the efficacy of targeted antifungal prophylaxis for the prevention of IA. In the meantime, each centre needs to evaluate its own recipient risk factors and rates of IA to determine whether these strategies are appropriate for its patients ([@b11-tcrm-4-1261]).

In conclusion, targeted prophylaxis against *Candida* and *Aspergillus* spp. is recommended in all SOT. Fluconazole should be used for prophylaxis against *Candida* spp. unless the institution has a high rate of non-*albicans* infections; conversely, voriconazole is recomended for prophylaxis against *Aspergillus* spp. allthough its significant interactions with immunosuppressive agents could be a potential limiting factor.

Targeted therapy of IFI in solid organ transplant patients
----------------------------------------------------------

With regard to the treatment, voriconazole, an extended spectrum highly lipophilic triazole with 98% oral bioavailability, is actually the first choice for initial therapy of IA in LT patients and other immunosuppressed hosts. Furthermore, the first experiences with LT patients also evidenced that continuous infusion of AmB is well tolerated, safe and efficient ([@b141-tcrm-4-1261]). Other potentially effective therapies include lipid formulations of AmB and echinocandins. Combination therapy using a triazole and an echinocandin has been evaluated in SOT, with a significant reduction in mortality in those patients with renal failure and infected by *A. fumigatus* ([@b132-tcrm-4-1261]).

In conclusion, IFIs, especially immunocompromised and critical care patients, have become an excellent target for prophylactic, empiric, and pre-emptive therapy interventions due to high morbidity and mortality rates, an increasing incidence, and associated health care costs. Early diagnosis and treatment are associated with a better prognosis. In all cases the choice of antifungal drug must be based on the individual characteristics of the patient. A tailored therapy (de-escalation) must also be considered in the ICU setting. Furthermore, risk-adapted prophylaxis is the best option in hematological and SOT patients.
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###### 

Usual susceptibility patterns for yeasts and moulds

  Species               Amphotericin B                                    Fluconazole                                         Itraconazole                                        Voriconazole                                   Posaconazole                                   Echinocandins
  --------------------- ------------------------------------------------- --------------------------------------------------- --------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------------------------------------
  *C. albicans*         S^a^                                              S                                                   S                                                   S                                              S                                              S
  *C. tropicalis*       S                                                 S                                                   S                                                   S                                              S                                              S
  *C. parapsilosis*     S                                                 S                                                   S                                                   S                                              S                                              S[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}
  *C. glabrata*         S, R                                              SDD, R[c](#tfn3-tcrm-4-1261){ref-type="table-fn"}   SDD, R[d](#tfn4-tcrm-4-1261){ref-type="table-fn"}   S[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}   S[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}   S
  *C. krusei*           S, R                                              R                                                   SDD, R[d](#tfn4-tcrm-4-1261){ref-type="table-fn"}   S[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}   S[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}   S
  *C. lusitaniae*       S, R[e](#tfn5-tcrm-4-1261){ref-type="table-fn"}   S                                                   S                                                   S                                              S                                              S
  *C. guilliermondii*   S, R                                              S, SDD                                              S                                                   S                                                                                             S
  *C. dubliniensis*     S, R[b](#tfn2-tcrm-4-1261){ref-type="table-fn"}   S, SDD, R                                           S                                                   S                                                                                             S
  *Trichosporon* spp.   S, R                                              S, SDD, R                                           S, SDD                                              S                                                                                             R
  *Blastoschizomyces*   S, R                                              S, SDD, R                                           S, SDD                                              S                                                                                             R
  *Malassezia* spp.     S, R                                              S                                                   S                                                   S                                                                                             ND
  *Rhodotorula* spp.    S                                                 S, SDD                                              S, SDD                                              S, SDD                                                                                        R
  *Cryptococcus* spp.   S                                                 S, SDD                                              S                                                   S                                              S                                              R
  *A. fumigatus*        S                                                 R                                                   S, R                                                S                                              S                                              S
  *A. terreus*          R                                                 R                                                   S                                                   S                                              S                                              S
  *A. niger*            S                                                 R                                                   S                                                   S                                              S                                              S
  *A. flavus*           S                                                 R                                                   S                                                   S                                              S                                              S
  *Fusarium solani*     R                                                 R                                                   R                                                   S                                              S                                              R
  *S. apiospermum*      R                                                 R                                                   R                                                   S                                              S                                              S
  *S. prolificans*      R                                                 R                                                   R                                                   R                                              R                                              R
  Zygomycetes           S                                                 R                                                   R                                                   R                                              S                                              R

**Notes:**S, susceptible; I, intermediate; R, resistant; SDD, susceptibility depends on the dose; ND, no data.

Susceptible, but few clinical data are available.

10%--15% of *C. glabrata* isolates are resistant to fluconazole.

Resistant to itraconazole \~50% and \~30% of *C. glabrata* and *C. krusei* isolates, respectively.

20% of isolates are resistant to amphotericin B.

###### 

Antifungal therapy strategies in ICU patients

                Strategy                                                                                                                                                        Antifungal agent                                                                                                                  References
  ------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------
  Prophylaxis   No generally recommended. Patients with upper gastrointestinal perforation, heavy *Candida* colonization or with severe acute pancreatitis might be benefited   Fluconazole                                                                                                                       [@b104-tcrm-4-1261]; [@b43-tcrm-4-1261]; [@b29-tcrm-4-1261]; [@b110-tcrm-4-1261]
  Empirical     Use of "*Candida* score" or the Ostrosky-Zeichner prediction rule                                                                                               De-escalation therapy (\*), the choice of antifungal drug must be based on the individual characteristics of the patient          [@b93-tcrm-4-1261]; [@b96-tcrm-4-1261]
  Pre-emptive   Based on detection of galactomannan, (1,3)-β-[d]{.smallcaps}-glucan or *C. albicans* germ tube antibodies                                                       De-escalation therapy (\*), the choice of antifungal drug must be based on the individual characteristics of the patient          [@b95-tcrm-4-1261]; [@b158-tcrm-4-1261]; [@b81-tcrm-4-1261]
  Targeted      Based on sterile site culture results                                                                                                                           De-escalation therapy (\*), the choice of antifungal drug must be based on the individual characteristics of the patient (\*\*)   [@b120-tcrm-4-1261]; [@b109-tcrm-4-1261]; [@b88-tcrm-4-1261]; [@b66-tcrm-4-1261]; [@b158-tcrm-4-1261]; [@b67-tcrm-4-1261]; [@b150-tcrm-4-1261]

**Notes:**An early broad-spectrum antifungal agent is initially prescribed, switching to a narrower-spectrum drug (fluconazole) when mycological identification and susceptibility studies are provided.

Focus on the presence of renal or hepatic failure, hemodynamic instability and possible interactions with other drugs.

###### 

Antifungal therapy strategies in hematological patients

                                    Strategy                                                                                                               Antifungal agent                               References
  --------------------------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------
  Prophylaxis                       High risk patients\*:                                                                                                  Itraconazole or Posaconazole or Voriconazole   [@b59-tcrm-4-1261]; [@b79-tcrm-4-1261]; [@b24-tcrm-4-1261]; [@b146-tcrm-4-1261]; [@b153-tcrm-4-1261]
  Intermediate risk patients\*\*:   Fluconazole                                                                                                                                                           
  Empirical                         Severely neutropenic cancer patients with persistent or relapsing fever despite broad-spectrum antibacterial therapy   Liposomal AmB or Caspofungin                   [@b54-tcrm-4-1261]; [@b149-tcrm-4-1261], [@b151-tcrm-4-1261]
  Pre-emptive                       Based on GM assays or CT or bronchoscopic cultures                                                                     Liposomal AmB or Caspofungin or Voriconazole   [@b74-tcrm-4-1261]
  Targeted                          Based on sterile site culture results                                                                                  Voriconazole Combination therapy               [@b50-tcrm-4-1261]; [@b78-tcrm-4-1261]; [@b16-tcrm-4-1261]

**Notes:**Acute leukemia patients, Allogenic HSCT recipients, autologous HSCT recipients, previous episode of IFI, rescue chemotherapy for acute leukemia patients and severe aplastic anemia.

Autologous HSCT recipients, acute linfoblastic leukemia, rescue therapy for myeloma and lymphomas.

###### 

Antifungal therapy strategies in lung transplantation (LT) recipients

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                Strategy                                                                                                                                                                                                 Antifungal agents                                                                                                            References
  ------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Prophylaxis   Generally recommended in the postoperative period                                                                                                                                                        Voriconazole or Amphotericin B (intravenous or aerosolized)                                                                  [@b18-tcrm-4-1261]; [@b86-tcrm-4-1261]; [@b55-tcrm-4-1261]; [@b33-tcrm-4-1261]; [@b71-tcrm-4-1261]

  Pre-emptive   Patients with pre- and/or post-transplant fungal airway colonization\                                                                                                                                    Voriconazole or Amphotericin B (intravenous or aerosolized)                                                                  [@b131-tcrm-4-1261]; [@b137-tcrm-4-1261]
                Patients with chronic rejection and respiratory samples positive for *Aspergillus*, mainly in single LT patients\                                                                                                                                                                                                                     
                Detection of galactomannan antigen of *Aspergillus*, (1,3)-β-[d]{.smallcaps}-glucan or *C. albicans* germ tube antibodies are not reliable methods with usefulness sufficiently demonstrated in the LT                                                                                                                                

  Targeted      Based on sterile site culture results or non-absolutely sterile samples (respiratory specimens) processed by semi or quantitative methods and considered clinically significant\                         Voriconazole or Amphotericin B or Echinocandins\                                                                             [@b50-tcrm-4-1261]; [@b132-tcrm-4-1261]
                AND/OR\                                                                                                                                                                                                  Combination therapy (triazole plus echinocandin) in those patients with LT and renal failure or infected by *A. fumigatus*   
                Based in histological studies of biopsies and other clinical specimens obtained by instrumental or chirurgic procedures (respiratory and non-respiratory samples)                                                                                                                                                                     
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Antifungal therapy strategies in recipients of nonpulmonary solid organ transplantation (NP-SOT)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                    Strategy                                                                                                                                                                          Antifungal agents                                                                                                                 References
  ----------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Prophylaxis**   Universal prophylaxis is not recommended\                                                                                                                                         Oral prophylaxis with nonabsorbable antifungal agents (nystatin, clotrimazole, amphotericin B) has shown inconsistent results.\   [@b72-tcrm-4-1261]; [@b155-tcrm-4-1261]; [@b135-tcrm-4-1261]; [@b154-tcrm-4-1261]; [@b41-tcrm-4-1261], [@b42-tcrm-4-1261]; [@b124-tcrm-4-1261]; [@b49-tcrm-4-1261], [@b48-tcrm-4-1261]; [@b92-tcrm-4-1261]; [@b19-tcrm-4-1261]
                    Antifungal prophylaxis adapted-to-risk is reasonable\                                                                                                                             Azoles (fluconazole, itraconazole) or Amphotericin B (lipid formulations) or Echinocandins (caspofungin)                          
                    High-risk NP-SOT recipients need to be identified in order to prevent the development of IFI                                                                                                                                                                                                                        

  **Pre-emptive**   Strategy not sufficiently validated in these patients\                                                                                                                            Azoles or Amphotericin B                                                                                                          [@b2-tcrm-4-1261]; [@b105-tcrm-4-1261]
                    Detection of galactomannan antigen of *Aspergillus*, (1,3)-β-[d]{.smallcaps}-glucan or *C. albicans* germ tube antibodies are not usefulness in NP-SOT recipients                                                                                                                                                   

  **Targeted**      Based on sterile site culture results or nonabsolutely sterile samples (respiratory specimens) processed by semi or quantitative methods and considered clinically significant\   Azoles or Amphotericin B or Echinocandins\                                                                                        [@b50-tcrm-4-1261]; [@b132-tcrm-4-1261]
                    AND/OR\                                                                                                                                                                           Combination therapy (triazole plus echinocandin) in patients with SOTand renal failure or infected by *A. fumigatus*              
                    Based in histological studies of biopsies and other clinical specimens obtained by instrumental or chirurgic procedures (respiratory and non-respiratory samples)                                                                                                                                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Etiological and clinical characteristics of IFI according to the type of SOT

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of transplant   Incidence of IFI (%)   Usual etiologic agent (s)                                Variables portending higher risk of IA                                                                                                                                                                                                         Mortality(%) of IA
  -------------------- ---------------------- -------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  Renal                0--20                  76%--95% *Candida* (mainly urinary tract infections),\   Graft failure requiring hemodialysis, high level and prolonged duration of corticosteroids                                                                                                                                                     77
                                              0%--25% *Aspergillus*                                                                                                                                                                                                                                                                                   

  Heart                5--20                  70%--90% *Aspergillus*, 8%--25% *Candida*                Isolation of *Aspergillus* species in respiratory tract cultures, reoperation, post-transplant hemodialysis, CMV disease                                                                                                                       78

  Liver                5--40                  35%--0% *Candida*, 9%--45% *Aspergillus*                 Retransplantation, renal failure (particularly requiring renal replacement therapy), fulminant hepatic failure as an indication for transplantation, primary allograft failure, high transfusion requirements, use of monoclonal antibodies,   87

  Lung/Heart--Lung     10--45                 43%--72% *Candida*, 25%--50% *Aspergillus*               Single lung transplant, CMV infection, rejection and augmented immunosuppression, obliterative bronchitis, *Aspergillus* colonization, acquired hypogammaglobulinemia, presence of bronchial stents, reperfusion injury, airway ischemia       68

  Pancreas (+kidney)   10--40                 \>90% *Candida*, 0%--3% *Aspergillus*                    Similar factors to the liver and kidney transplant, graft lost (vascular graft thrombosis, post-reperfusion pancreatitis), enteric drainage, alemtuzumab-containing immunosuppresive regimen                                                   100

  Small bowel          30--60                 80%--100% *Candida*, 0%--5% *Aspergillus*                Not clearly determined, similar factors to others intraabdominal SOT recipients; Graft rejection/dysfunction, enhanced immunosuppression, anastomotic disruption, multi-visceral transplant                                                    66
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** SOT, solid organ transplantation/solid organ transplant recipients; IFI, invasive fungal infection; IA, invasive aspergillosis; CMV, cytomegalovirus.
